Peptide prices explained.

Peptide prices run from about $0.50 to $80 per milligram, and four synthesis variables explain nearly all of that spread. One vendor lists BPC-157 at $55, another at $90, a third at $19. We’ll show you where the cost floor sits, and why a price below it is a question rather than a bargain.

This article is the cost-math companion to our buyer’s guide. That piece answers how you evaluate a vendor. This one answers how you evaluate a price.

The two questions share an answer. The documentation chain that proves a peptide is what the label claims is also the cost a vendor has to recover in the per-vial price.

The four levers that drive peptide pricing

Peptide prices come down to four variables, every one rooted in how the molecule is physically built. None of them are marketing decisions. They’re consequences of the chemistry described in the industrial SPPS literature by Verlander, 2007.

1. Sequence length — each amino acid is one more cycle

Solid-phase peptide synthesis (SPPS) builds a peptide one residue at a time on a polystyrene bead. Each cycle deprotects, couples a new amino acid, and washes. GHK-Cu needs 3 cycles. BPC-157 needs 15. Tirzepatide needs 39.

Each cycle hits roughly 98–99.5% coupling efficiency. A 5-residue peptide retains about 95% of starting material. A 40-residue peptide at the same per-cycle efficiency keeps only 67%.

So the longer peptide isn’t just 8× the cycles. It’s a messier crude mixture that costs more HPLC time to clean up. That’s why a tetrapeptide and a 40-residue compound sit roughly an order of magnitude apart per mg.

2. Chemical modifications — specialty chemistry adds specialty cost

Standard SPPS handles the 20 normal L-amino acids efficiently. Anything beyond that costs more:

• D-amino acids. SS-31 contains D-arginine. D-residues provide protease resistance but cost 3–10× the equivalent L-residue.
• Lipidation. Tirzepatide has a fatty-acid side chain at lysine-20; retatrutide has a similar long-chain modification. These enable once-weekly dosing through albumin binding but add on-resin acylation and extra purification.
• PEGylation. PEG attachment extends half-life but requires conjugation chemistry and characterization separate from the synthesis itself.
• Unnatural residues. Aib (aminoisobutyric acid) appears in semaglutide for protease resistance. Non-canonical amino acids cost more than the natural set.
• Cyclization. Disulfide bridges, head-to-tail cyclization, or side-chain stapling all add steps after the linear sequence is built.

Tesamorelin is the textbook case. The 44-residue GHRH(1-44) backbone is long but standard SPPS handles it. The N-terminal trans-3-hexenoyl modification is what turns it into tesamorelin (rather than sermorelin), and what makes it meaningfully more expensive per mg.

3. Purification rigor — 95% vs 99% is mostly column time

The 2026 working standard for third-party tested research peptide purity is ≥98% HPLC. Leading suppliers reach 99%+ (Verlander, 2007). Tightening the preparative HPLC collection window from 95% to 99% means rejecting more borderline fractions and cutting yield by 10–30%. Cost-per-mg goes up accordingly.

This is the lever behind most price gaps between vendors selling “the same” peptide. Two suppliers can buy crude peptide from the same contract manufacturer. One purifies to 95% and sells for $30. The other purifies to 99% with a documented chromatogram and sells for $75.

The synthesis source is identical. The purification depth isn’t. So the cheaper vial isn’t the same product you’d get from the other one; it carries a different impurity profile.

4. Documentation overhead — third-party testing is a real cost

A CoA from an ISO/IEC 17025–accredited third-party lab costs the supplier $150–$400 per lot for HPLC, mass-spec identity and water content. Bacterial endotoxin testing under USP <85> adds another $80–$200 per lot.

Storage stability data, serialized lot traceability and the quality system behind them are ongoing costs too. Small per vial, but real. And zero for the vendors who skip them.

BPC-157

$5–$10/mg ≥99% pure Synthesis-justified pricing

The 15-residue gastric pentadecapeptide sits at the class median for tissue-repair peptides — the same compound cited across the 2025 BPC-157 literature review and the 2025 HSS Journal systematic review. Lab-verified identity, ISO 17025 third-party CoA on every lot, priced to reflect synthesis and documentation cost rather than race-to-the-bottom shortcuts.

Shop BPC-157

Cost per cycle — what research actually costs

Cost-per-mg is the supplier’s economics. Cost-per-cycle is yours. The two diverge because compound quantities and study durations differ widely across classes. We’ve worked three examples that span the price spectrum.

BPC-157 — the “cheap peptide” case

Published BPC-157 preclinical studies have investigated doses that translate to roughly 7 mg of compound across a 4-week study period. A single 10 mg vial covers that, with about 3 mg to spare.

At class-median pricing, a 4-week cycle costs you roughly $50–$100 in peptide, plus a $10–$15 vial of bacteriostatic water spread across several cycles. The economics are forgiving because the quantities are microgram-scale and per-mg cost is low.

Tirzepatide — the GLP-1 reality check

The SURMOUNT-1 clinical trial investigated tirzepatide on an 8-week dose-escalation schedule of 2.5, 5, 7.5 then 10 mg a week. That consumes roughly 50 mg of compound across the titration.

At the class median of $40–$80/mg, an 8-week supply costs $1,000–$2,000. That’s an order of magnitude above BPC-157, because a 39-residue lipidated peptide isn’t a $50 compound to synthesize.

So a $40 vial of “tirzepatide” from an unfamiliar source is almost certainly misidentified, underdosed or substantially impure. The synthesis-cost floor doesn’t bend.

GHK-Cu — the cosmetic-bulk case

In vitro and dermatology studies have investigated GHK-Cu at concentrations corresponding to very small quantities per application. A 50 mg vial, the typical commercial format, supports months of in vitro or topical work.

Per-cycle cost is roughly $40–$80 for the whole vial, which makes it a multi-month supply rather than a per-cycle expense. Three things keep it cheap: the tripeptide is easy to synthesize, the research quantities are small, and the manufacturing is mature.

Why cheap is suspicious — the synthesis-cost floor

There’s a real floor below which the math doesn’t add up. It isn’t a vendor decision. It’s a consequence of synthesis cost, purification depth, and third-party testing. A supplier below the floor has skipped something. What they’ve skipped is what determines whether the molecule in the vial is what the label claims.

Three below-floor signals:

• Any 10 mg peptide vial priced below $30. Wholesale synthesis cost of even the cheapest tripeptide plus reasonable margins sits around $25–$35. A 10 mg BPC-157 vial at $19 retail (a real listing at low-tier vendors) is below the cost to produce a CoA, let alone the cost to produce the peptide.
• $5–$10 vials of any peptide. At that price the contents are almost always under-dosed (a few mg labeled as 10 mg), substantially impure (sub-90% purity), misidentified entirely, or mostly diluent. The chemistry doesn’t support real third-party tested research peptide here.
• $50–$80 vials of lipidated GLP-1 analogs. Tirzepatide and retatrutide at one-fifth to one-tenth class-median price are essentially impossible inside the ISO 17025-testable supply chain. The 39-residue backbone plus lipidation plus third-party identity verification doesn’t fit that envelope. The vial is either a non-tirzepatide compound under a tirzepatide label, or it’s sold without the testing chain that would let you verify.

Why prices vary between reputable vendors

Even above the synthesis-cost floor, prices vary by roughly 30–50% across the market for the same peptide. The variation tracks four legitimate cost-stack differences:

• Synthesis source. Vendors buying crude peptide from established U.S. contract manufacturers (Bachem, AmbioPharm, PolyPeptide) pay more than vendors sourcing from smaller Asian manufacturers. Quality is more consistent at the established shops, and wholesale cost reflects that.
• Purification depth. A vendor consistently delivering 99.5%+ purity carries roughly 15–25% more cost per mg than one delivering 98%.
• Third-party testing thoroughness. Per-lot external testing costs more than batch sampling (one external CoA per 5–10 lots) with internal QC on the rest. The first approach produces granular traceability. The second is cheaper.
• Operational overhead. U.S. fulfillment, named lab partners, published return policy, real customer service, a warehouse with proper storage, lot traceability back to the buyer — all real operating costs. Re-shippers drop-shipping from an Asian manufacturer carry almost none of these. The difference shows up in the buyer experience, not the molecule: missing orders, slow shipping, no recourse when a lot tests out of spec.

A 30–50% gap between reputable suppliers usually maps to one of these four. A 5× or 10× gap doesn’t. That’s the floor versus the cellar.

The Peptriva catalog

22 SKUs Class-median pricing No race-to-bottom

The full Peptriva catalog is priced to sit at or near class median — tissue-repair peptides at $5–$10/mg, GH-axis at $5–$25/mg, GLP-1 class at $40–$80/mg. Every lot ships with a batch-matched ISO 17025 third-party CoA. COAs available before purchase on request — the synthesis-cost floor is not a marketing claim.

Learn more

Frequently asked questions about peptide prices

How much do peptides cost?

Research peptide prices span roughly an order of magnitude by class. Dermal peptides like GHK-Cu run $0.50–$2/mg. Tissue-repair peptides like BPC-157 run $5–$10/mg, or $50–$100 per 10 mg vial.

GH-axis secretagogues like CJC-1295 or ipamorelin run $5–$25/mg. GLP-1 peptides like tirzepatide and retatrutide run $40–$80/mg, or $200–$400 per 10 mg vial. The gap is synthesis complexity, not vendor markup.

Why is tirzepatide so expensive?

Tirzepatide is a 39-residue peptide with a fatty-acid side chain at lysine-20. Thirty-nine coupling cycles, specialized lipidation chemistry and a longer crude mixture to purify all compound together.

The result is a per-mg cost roughly 10× that of an unmodified 15-residue peptide like BPC-157. A “cheap tirzepatide” at $50 per 10 mg vial is almost certainly not tirzepatide as labeled.

Are cheap peptides safe?

Cheap peptides should prompt identity questions, not bargain enthusiasm. A 10 mg vial priced under $30 has almost certainly skipped purification, third-party testing or both.

What arrives may not be what the label claims. It could be underdosed, a different peptide entirely, or substantially impure. Safety isn’t the right framing here; identity is. Without third-party testing, you don’t know what’s in the vial.

How much does a BPC-157 research cycle cost?

Published BPC-157 preclinical studies have used quantities that translate to approximately 7 mg consumed over a 4-week study period. At $5–$10/mg, that is $35–$70 in peptide cost. A single 10 mg vial covers one study cycle, bringing all-in cost to roughly $50–$100, plus a $10–$15 vial of bacteriostatic water amortized across multiple cycles.

What’s the cheapest peptide?

GHK-Cu, a copper-bound tripeptide, is the cheapest research peptide per mg at $0.50–$2. It’s short, its synthesis is mature after decades of cosmetic-scale production, and it’s sold in 50 mg vials rather than 5 or 10.

Short cognitive peptides like Selank, Semax and DSIP come next at $3–$8/mg. They’re heptapeptides or nonapeptides needing only 7 to 9 cycles.

Why do prices vary so much between vendors?

Variation tracks four cost-stack differences: synthesis source, purification depth, third-party testing thoroughness and operational overhead. U.S. contract manufacturers cost more than smaller Asian sources, and U.S. fulfillment with named lab partners and lot traceability costs more than drop-shipping.

A 30–50% gap between two reputable suppliers usually maps to one of those four. A 5× gap doesn’t. That’s a sign one supplier skipped purification or testing.